Johnson & Johnson Requests Emergency Authorization for COVID-19 Vaccine


Pharmaceutical giant, Johnson & Johnson has requested emergency use authorization from the Food and Drug Administration. The company submitted its application Thursday for the company’s single-dose inoculation.

In a statement to the press, the company said if emergency use is granted, it aims to supply 100 million doses in the first half of 2021. Unlike Pfizer and Moderna, Johnson & Johnson’s Janssen vaccine can be stored for at least three months at 36-46 degrees Fahrenheit, compatible with standard vaccine distribution channels, the company said.

“Today’s submission for Emergency Use Authorization of our investigational single-shot COVID-19 vaccine is a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “Upon authorization of our investigational COVID-19 vaccine for emergency use, we are ready to begin shipping. With our submission to the FDA and our ongoing reviews with other health authorities around the world, we are working with great urgency to make our investigational vaccine available to the public as quickly as possible.”

The FDA is expected to hold the first meeting of outside advisers on the application on Feb. 26. If the FDA panel favors the vaccine, a decision to authorize its use could come soon after.